During the corresponding time, Kiniksa Pharmaceuticals International Plc recorded a revenue increase by 55.51 % year on year, sequentially revenue grew by 6.01 %. While revenue at the Kiniksa Pharmaceuticals International Plc's corporate clients
Kiniksa Pharmaceuticals International Plc's Comment on Sales, Marketing and Customers
The company provides services to government agencies including the Veterans Administration, Department of Defense (covering military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and Public Health Service (PHS). It also serves hospitals that cater to a disproportionate share of financially needy patients, community health clinics, and other entities receiving health services grants from the PHS under the 340B Drug Pricing Program. The company's markets are influenced by federal and state drug pricing regulations and healthcare reform initiatives such as Medicaid, Medicare Parts B and D, and the Inflation Reduction Act (IRA) of 2022, which affect drug pricing, rebates, and negotiation programs. The company is subject to pricing caps, discounts, and reporting requirements associated with these programs and legislation.
Kiniksa Pharmaceuticals International Plc’s Comment on Sales, Marketing and Customers
The company provides services to government agencies including the Veterans Administration, Department of Defense (covering military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and Public Health Service (PHS). It also serves hospitals that cater to a disproportionate share of financially needy patients, community health clinics, and other entities receiving health services grants from the PHS under the 340B Drug Pricing Program. The company's markets are influenced by federal and state drug pricing regulations and healthcare reform initiatives such as Medicaid, Medicare Parts B and D, and the Inflation Reduction Act (IRA) of 2022, which affect drug pricing, rebates, and negotiation programs. The company is subject to pricing caps, discounts, and reporting requirements associated with these programs and legislation.
Sources:
Kiniksa Pharmaceuticals International Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kiniksa Pharmaceuticals International Plc’s corporate clients.
For your research, we’ve provided 9 tables on Kiniksa Pharmaceuticals International Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %